Number of shares and votes in BioArctic AB (publ) as of November 28, 2025 November 28, 2025 18:30 Regulatory Read more
New drug application for subcutaneous formulation of Leqembi[®] submitted in Japan November 28, 2025 06:30 Regulatory Read more
Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose November 25, 2025 13:37 Regulatory Read more
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025 October 30, 2025 11:00 Regulatory Read more
Leqembi® approved for IV maintenance treatment in China September 29, 2025 08:15 Regulatory Read more
Leqembi® approved for the treatment of early Alzheimer’s disease in Australia September 24, 2025 08:40 Regulatory Read more
BioArctic’s founders intend to divest minor part of their shareholding September 3, 2025 17:35 Regulatory Read more
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer’s disease under Fast Track status September 3, 2025 01:30 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of August 29, 2025 September 1, 2025 18:30 Regulatory Read more
US FDA approves Leqembi® IQLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease August 29, 2025 23:55 Regulatory Read more
BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties August 26, 2025 07:05 Regulatory Read more
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025 July 31, 2025 12:00 Regulatory Read more
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review June 13, 2025 08:00 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of May 30, 2025 May 30, 2025 18:30 Regulatory Read more
Bulletin from the Annual General Meeting in BioArctic AB (publ) May 22, 2025 18:18 Regulatory Read more
BioArctic receives positive opinion for Orphan Medicinal Product Designation in the EU for exidavnemab in Multiple System Atrophy May 22, 2025 15:15 Regulatory Read more
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 – March 2026) May 15, 2025 06:00 Regulatory Read more
Sales of Leqembi[®] totaled 14.7 billion yen in the first quarter 2025 May 1, 2025 12:45 Regulatory Read more
Notice of Annual General Meeting 2025 in BioArctic AB (publ) April 22, 2025 20:00 Regulatory Read more
BioArctic publishes the Annual Report and Sustainability Report for 2024 April 22, 2025 20:00 Regulatory Read more
EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease (Extended information) April 16, 2025 01:10 Regulatory Read more
EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease April 15, 2025 17:25 Regulatory Read more
The European Commission to make final decision on EU Marketing Authorisation for lecanemab April 14, 2025 13:00 Regulatory Read more
Exidavnemab and lecanemab data presented at the 2025 AD/PD™ congress April 7, 2025 12:00 Regulatory Read more
The European Commission refers lecanemab decision to Appeal Committee April 1, 2025 12:00 Regulatory Read more
BioArctic’s partner Eisai presents sales simulation for Leqembi® at its annual press conference March 25, 2025 07:50 Regulatory Read more
BioArctic receives Orphan Drug Designation for exidavnemab the US March 17, 2025 18:25 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of February 28, 2025 February 28, 2025 18:30 Regulatory Read more
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s disease in the EU February 28, 2025 14:00 Regulatory Read more
BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing February 20, 2025 06:30 Regulatory Read more
Leqembi® sales reaches €200 million – first sales milestone achieved February 18, 2025 08:00 Regulatory Read more
Sales of Leqembi® totaled 13.3 billion yen in the fourth quarter 2024 February 7, 2025 04:35 Regulatory Read more
Update on regulatory review of lecanemab for treatment of early Alzheimer’s disease in the European Union January 31, 2025 12:30 Regulatory Read more
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer’s Disease in the US January 27, 2025 00:30 Regulatory Read more
